SAN JOSE, Calif. — January 20, 2026 — Leads & Copy — BrightInsight has secured $13 million in a new investment round to advance its AI-driven medication adherence solutions and expand its high-impact programs.
The funding, which includes participation from existing and new investors such as Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners, will support the rapid scaling of programs like the Patient App, a collaboration with Sanofi and Regeneron, across various diseases and therapies worldwide.
BrightInsight is addressing the critical issue of medication non-adherence, which CEO & Co-Founder Kal Patel says sees 30-70% participation rates in deployed programs, with similar percentages of patients continuing to use the solutions a year later. These results are consistent across different diseases and patient populations, according to Patel.
Medication non-adherence affects roughly 50% of patients with chronic diseases. This leads to 125,000 preventable deaths annually and accounts for up to 25% of all hospitalizations in the U.S.
This problem creates between $100 billion and $300 billion in avoidable healthcare expenses each year due to unnecessary provider visits, emergency treatments, and prolonged hospital stays.
New Leaf Venture Partners Managing Director Vijay Lathi says that BrightInsight has demonstrated its ability to scale a platform that addresses a critical market need, leading to their increased investment.
With the new capital, BrightInsight plans to enhance its product and solution roadmap by integrating AI to deliver user-specific insights and predictions, such as medication churn, expand its disease-specific partner ecosystem, and broaden the platform to include caregivers and nurse educators.
BrightInsight’s Chief Operating Officer Robert Zdon says that the company can use AI to better predict medication churn and deliver personalized interventions that help patients stay on therapy and achieve better outcomes by combining data with advanced AI.
BrightInsight is a platform for biopharma compliant digital health solutions. It enables life sciences companies to develop, launch, and scale digital solutions, including patient companion apps, digital-first patient support programs (PSP), and Software as a Medical Device (SaMD) solutions.
Customers partner with BrightInsight to differentiate their therapies and use real-world data to drive measurable business and clinical value.
Contact: Helen Shik, Shik Communications for BrightInsight, Helen@ShikCommunications.com, 617-510-4373
Source: BrightInsight
